Skip to main content
ABCL logo

AbCellera Biologics Inc.

ABCLNASDAQHealthcareBiotechnology

$11.80Today:- (-)1Y +126.83%

As of Oct 16, 2026 close

Market cap
$3.87B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$2.75$15.02
Volume (live)
-
Avg. volume (3M)
5.02M

AbCellera Biologics (ABCL) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), AbCellera Biologics used $131.29M of cash in operating activities and spent $42.77M on capital expenditures. That left free cash flow of −$174.07M.

AbCellera Biologics Cash Flow Statement Analysis

Values in billions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for AbCellera Biologics Inc. (ABCL) - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-0.15-0.16-0.150.160.150.120.000.00
Depreciation & Amortization0.020.100.030.030.020.010.000.00
Deferred Income Tax0.000.000.000.000.000.000.000.00
Stock Based Compensation0.060.070.060.050.000.010.000.00
Change in Working Capital-0.07-0.030.010.030.04-0.120.000.00
Change in Accounts Receivable-0.06-0.08-0.050.110.02-0.200.000.00
Change in Inventory0.000.000.020.000.000.000.000.00
Change in Accounts Payable0.000.01-0.020.000.000.010.000.00
Change in Other Working Capital-0.020.010.060.000.020.080.000.00
Other Operating Activities0.01-0.08-0.010.010.030.000.000.00
Net Cash from Operating Activities-0.13-0.11-0.040.280.240.020.000.00
Investing Activities
Capital Expenditures-0.04-0.08-0.08-0.07-0.06-0.010.00-0.01
Acquisitions0.00-0.02-0.01-0.03-0.01-0.110.000.00
Purchases of Investments-0.44-0.78-1.07-0.79-0.320.000.000.00
Sales/Maturities of Investments0.000.940.910.510.030.000.000.00
Other Investing Activities0.570.050.030.000.030.000.000.00
Net Cash from Investing Activities0.090.12-0.22-0.35-0.33-0.12-0.01-0.01
Financing Activities
Debt Repayment0.000.010.010.000.000.090.000.00
Common Stock Issued0.000.000.000.000.000.520.000.00
Other Financing Activities0.010.000.000.00-0.010.080.000.01
Net Cash from Financing Activities0.010.010.010.000.000.680.000.01
Summary
Effect of Forex Changes on Cash0.000.000.00-0.010.000.000.000.00
Net Change in Cash-0.030.02-0.25-0.09-0.090.590.000.01
Cash at Beginning of Period0.180.160.410.500.590.010.010.00
Cash at End of Period0.160.180.160.410.500.590.010.01
Free Cash Flow-0.17-0.19-0.120.210.190.010.000.00

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About AbCellera Biologics Cash Flow

What is AbCellera Biologics's free cash flow?

AbCellera Biologics had negative free cash flow of $174.07M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$131.29M minus $42.77M of capital expenditures.

How much does AbCellera Biologics spend on capital expenditures?

AbCellera Biologics spent $42.77M on capital expenditures in fiscal 2025, compared with $78.40M a year earlier.

Does AbCellera Biologics pay dividends or buy back shares?

AbCellera Biologics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition